ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways

Lignende værker

• A novel variant of ER-alpha, ER-alpha36 mediates testosterone-stimulated ERK and Akt activation in endometrial cancer Hec1A cells
  af: Lin, Sheng-Li, et al.
  Udgivet: (2009)
• Estrogen receptor variant ER‐α36 promotes tamoxifen agonist activity in glioblastoma cells
  af: Qu, Chao, et al.
  Udgivet: (2019)
• ER-α36, a novel variant of ER-α, mediates estrogen-stimulated proliferation of endometrial carcinoma cells via the PKCδ/ERK pathway.
  af: Jing-Shan Tong, et al.
  Udgivet: (2010-11-01)
• ER-α36, a Novel Variant of ER-α, Mediates Estrogen-Stimulated Proliferation of Endometrial Carcinoma Cells via the PKCδ/ERK Pathway
  af: Tong, Jing-Shan, et al.
  Udgivet: (2010)
• Tamoxifen and ERα36: Fertilizing the seeds of breast cancer metastasis
  af: Burness, Monika L., et al.
  Udgivet: (2018)